Cover Image
Market Research Report

Phototherapies for Psoriasis - Market Insights, Epidemiology and Market Forecast - 2027

Published by DelveInsight Business Research LLP Product code 703428
Published Content info 180 Pages
Delivery time: 1-2 business days
Price
Back to Top
Phototherapies for Psoriasis - Market Insights, Epidemiology and Market Forecast - 2027
Published: September 1, 2018 Content info: 180 Pages
Description

DelveInsight's "Phototherapies for Psoriasis - Market Insights, Epidemiology and Market Forecast - 2027" report provides an overview of the disease pathogenesis, Biomarkers, various diagnostic approaches and treatment algorithm including detailed chapters for marketed products and various marketed products patent details. The report also includes in depth research related to Phototherapies for Psoriasis for the 7MM including United States, EU-5 (Germany, France, Italy, Spain and UK) and Rest of the world for the study period undertaken from 2015-2027.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Rest of the world

Study Period: 2016-2027

Phototherapies for Psoriasis Understanding and Treatment

The report provides the in depth analysis of the disease overview by providing details such as disease definition, symptoms, causes, pathogenesis, biomarkers, co-morbid conditions with psoriasis, different diagnostic approaches and guidelines of various regulatory bodies to treat and manage the psoriasis and treatment algorithm are also provided in the report.

Psoriasis is fundamentally an inflammatory skin condition with reactive abnormal epidermal differentiation and hyperproliferation which affects 2-3% of world's population. The pathophysiology of the disease includes mainly the activation and migration of T-cells to the dermis triggering the release of cytokines (tumor necrosis factor-alpha, TNF-alpha in particular) which lead to the inflammation and the rapid production of skin cells. A number of factors are responsible for triggering psoriasis. Among factors known to induce or worsen psoriasis are: mild localized trauma, such as scratching, piercings, tattoos, sunburns, chemical irritant, drugs including beta-blockers, lithium, anti-malarials, and non-steroidal anti-inflammatory drugs, HIV infection, and Stereptococcal pharyngitis. The climate in general and exposure to natural sun light in particular act as additional extrinsic factors with clinically important impacts on disease activity. Another factor of central importance is genetics.

Psoriasis Epidemiology Insights

This section provide the insights about the historical and current patient pool and forecasted trend segmented by 7 major markets. It enables understanding of the historical and forecasted epidemiological data for the prevalent cases of Psoriasis. Across 7MM, Psoriasis prevalent cases demonstrated an increasing trend and are forecasted to rise further in the coming years. Some of the key findings include:

  • The prevalent cases of Psoriasis in adult population in 7MM was reported to be 35,396 in 2016
  • The prevalence of Psoriasis in 2016 was highest in the United States, followed by theUnited kingdom
  • As per the estimates of DelveInsight, the prevalence of Psoriasis is expected to reach up to 4809 cases in 2020 in Italy
  • In 2016, the prevalent population of Psoriasis was 10,627 cases in United Kingdom

Phototherapies for Psoriasis Market Share by Therapies

This section focusses on the rate of uptake of the phototherapy for the treatment of psoriasis in the market during the study period from 2016-2027. A detailed historical market analysis has been conducted by DelveInsight for Phototherapies for Psoriasis, and currently, the market comprises of broad band ultraviolet, psoralen ultraviolet, low-level light/laser therapy, red light, blue light, and other different light and laser sources are available as first line to third line therapies depend up on the severity and localized part of psoriasis. Other research and development activities are set to add more combination therapies with phototherapy includes addition of topical agents, vitamin analogues and various systemic therapeutic candidates. This combinations and various laser sourced treatment for psoriasis reached the market and expand its global reach. DelveInsight projected current scenario and future scope for the treatment of psoriasis with phototherapy from 2016-2027.

Phototherapy for Psoriasis: 7 Major Market Analysis

This part of the Phototherapy for Psoriasis report encloses the detailed analysis of market size in US, EU5 countries for period of 2016-2027. United States had the highest market size of Phototherapy for Psoriasis in 2016, which accounts for approximately 55.71% of total 7MM market. The market was divide based on the phototherapy type and by end user application.

Epidemiology segmentation of Psoriasis

The report comprises of epidemiology section of total prevalent population by region wise, total diagnosed prevalent population, Severity specific diagnosed and treatable population by therapies and treatable population segmentation by the use of phototherapy across the 7MM regions.

Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Key Coverage

  • Understanding historical and forecasted epidemiological data for Phototherapies for Psoriasis - Market Insights, Epidemiology and Market Forecast covering 7MM from 2016-2027.
  • Segment level epidemiology and market split for Phototherapies for Psoriasis - Market Insights, Epidemiology and Market Forecast.
  • The thorough assessment of market, current trends & future scope along with upcoming combination with Phototherapies for Psoriasis.
  • The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and RoW) from 2016-2027 and detailed historical and forecasted Phototherapies for Psoriasis - Market Insights, Epidemiology and Market Forecast market trends.
  • Thorough market distribution based on market share for Phototherapies for Psoriasis - Market Insights, Epidemiology and Market Forecast.

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Phototherapies for Psoriasis - Market Insights, Epidemiology and Market Forecast market.
  • To understand the future market scenario in the Phototherapies for Psoriasis - Market Insights, Epidemiology and Market Forecast market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Phototherapies for Psoriasis - Market Insights, Epidemiology and Market Forecast in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Rest of the world.
  • Identification of future scope in market will help in devising strategies that will help in getting ahead of competitors.
Table of Contents
Product Code: DIMI0347

Table of Contents

1 Key Insights

2 Rosacea: Market Overview at a Glance

  • 2.1 Total Market Share (%) Distribution of phototherapy for psoriasis in 2016
  • 2.2 Total Market Share (%) Distribution of phototherapy for psoriasis in 2027

3 Introduction

4 Disease Background and Overview: Psoriasis

  • 4.1 Classification of Psoriasis
  • 4.2 Signs and symptoms
  • 4.3 Risk Factors
  • 4.4 Pathogenesis
  • 4.5 Comorbidities of Psoriasis
  • 4.6 Biomarkers
    • Soluble Biomarkers
    • Tissue-Associated Biomarkers
    • Other Biomarkers

5 Diagnosis

  • 5.1 Differential Diagnosis

6 Epidemiology and Patient Population

  • 6.1 Key Findings

7 Total Prevalent Patient Population of Psoriasis in the US & EU5

8 Total Treatable Patient Population of Psoriasis by Phototherapies in the US and EU5

9 Country Wise-Epidemiology of Psoriasis

  • 9.1 United States
    • Total Prevalent Population of Psoriasis in the United States
    • Total Diagnosed Prevalent Population of Psoriasis in the United States
    • Severity Specific Diagnosed Prevalent Population of Psoriasis in the United States
    • Treatable Population of Psoriasis by Therapies in the United States
    • Treatable Population of Psoriasis by Phototherapies in the United States
  • 9.2 EU5 Countries
  • 9.3 Germany
    • Total Prevalent Population of Psoriasis in Germany
    • Total Diagnosed Prevalent Population of Psoriasis in Germany
    • Severity Specific Diagnosed Prevalence of Psoriasis in Germany
    • Treatable Population of Psoriasis by Therapies in Germany
    • Treatable Population of Psoriasis by Phototherapies in Germany
  • 9.4 France
    • Total Prevalent Population of Psoriasis in France
    • Total Diagnosed Prevalent Population of Psoriasis in France
    • Severity Specific Diagnosed Prevalence of Psoriasis in France
    • Treatable Population of Psoriasis by Therapies in France
    • Treatable Population of Psoriasis by Phototherapies in France
  • 9.5 Italy
    • Total Prevalent Population of Psoriasis in Italy
    • Total Diagnosed Prevalent Population of Psoriasis in Italy
    • Severity Specific Diagnosed Prevalence of Psoriasis in Italy
    • Treatable Population of Psoriasis by Therapies in Italy
    • Treatable Population of Psoriasis by Phototherapies in Italy
  • 9.6 Spain
    • Total Prevalent Population of Psoriasis in Spain
    • Total Diagnosed Prevalent Population of Psoriasis in Spain
    • Severity Specific Diagnosed Prevalence of Psoriasis in Spain
    • Treatable Population of Psoriasis by Therapies in Spain
    • Treatable Population of Psoriasis by Phototherapies in Spain
  • 9.7 United Kingdom
    • Total Prevalent Population of Psoriasis in the United Kingdom
    • Total Diagnosed Prevalent Population of Psoriasis in the United Kingdom
    • Severity Specific Diagnosed Prevalence of Psoriasis in the United Kingdom
    • Treatable Population of Psoriasis by Therapies in the United Kingdom
    • Treatable Population of Psoriasis by Phototherapies in the United Kingdom

10 Treatment

  • 10.1 Nonpharmacologic
  • 10.2 Topical Therapy
  • 10.3 Systemic Therapy
  • 10.4 Biologic Therapy

11 Treatment Algorithm

  • 11.1 Psoriasis clinical guideline: American Academy of Dermatology
    • Biologics therapy
    • Topical Therapy
    • Systemic Therapies
    • Phototherapy
    • NHS Guidelines and management of Psoriasis
    • Guidelines for the management of patients with Psoriasis

12 Phototherapies

  • 12.1 Conditions that can be treated with phototherapy
  • 12.2 What does phototherapy involve?
  • 12.3 Effectiveness of Phototherapy
  • 12.4 Potential side effects of Phototherapy
  • 12.5 Clinical effects of Ultraviolet light and the regulatory pathways
  • 12.6 Phototherapy for Psoriasis
  • 12.7 Phototherapy in combination

13 Current Scenario & Future Scope

14 Unmet Needs

15 Phototherapy for Psoriasis: 7 Major Market Analysis

  • 15.1 Key Findings
  • 15.2 Market Size of Phototherapy for Psoriasis in the US, EU5, and RoW

16 The United States Market Outlook

  • United States Market Size
  • Total Market size of Phototherapy for Psoriasis
  • Market Size by Phototherapy type
  • Market Size by End Users

17 EU5 Market Outlook

  • Total Market size of Phototherapy for Psoriasis
  • Market Size by Phototherapy type
  • Market Size by End Users

18 France Market Size

  • Total Market size of Phototherapy for Psoriasis
  • Market Size by Phototherapy type
  • Market Size by End Users

19 Italy Market Size

  • Total Market size of Phototherapy for Psoriasis
  • Market Size by Phototherapy type
  • Market Size by End Users

20 Spain Market Size

  • Total Market size of Phototherapy for Psoriasis
  • Market Size by Phototherapy type
  • Market Size by End Users

21 United Kingdom Market Size

  • Total Market size of Phototherapy for Psoriasis
  • Market Size by Phototherapy type
  • Market Size by End Users

21 RoW Market Outlook

  • Total Market size of Phototherapy for Psoriasis

22 Market Driver

23 Market Barriers

24 Appendix

  • Report Methodology

25 DelveInsight Capabilities

26 Disclaimer

27 About DelveInsight

List of Tables

  • Table 1: Features which have been considered in different classifications of Psoriasis
  • Table 2: Signs and Symptoms of Psoriasis
  • Table 3: Common Comorbidities of Psoriasis
  • Table 4: Biomarkers for Psoriasis
  • Table 5: Measure of disease severity
  • Table 6: Objective Assessments
  • Table 7: Subjective Assessments
  • Table 8: Differential diagnoses and distinguishing clinical features
  • Table 9: Total Prevalent Population of Psoriasis in the United States and EU5 (2016-2027)
  • Table 10: Total Treatable Patient Population of Psoriasis by Phototherapies in United States and EU5 (2016-2027)
  • Table 11: Total Prevalent Population of Psoriasis in the United States (2016-2027)
  • Table 12: Total Diagnosed Prevalent Population of Psoriasis in the United States (2016-2027)
  • Table 13: Severity Specific Diagnosed Prevalence of Psoriasis in the United States (2016-2027)
  • Table 14: Treatable Population of Psoriasis by Phototherapy in the United States (2016-2027)
  • Table 15: Treatable Population of Psoriasis by Phototherapies type in the United States (2016-2027)
  • Table 16: Total Prevalent Population of Psoriasis in Germany (2016-2027)
  • Table 17: Total Diagnosed Prevalent Population of Psoriasis in Germany (2016-2027)
  • Table 18: Type Specific Diagnosed Prevalence of Psoriasis in Germany (2016-2027)
  • Table 19: Treatable Population of Psoriasis by Therapies in the Germany (2016-2027)
  • Table 20: Treatable Population of Psoriasis by Phototherapies type in Germany (2016-2027)
  • Table 21: Total Prevalent Population of Psoriasis in France (2016-2027)
  • Table 22: Total Diagnosed Prevalent Population of Psoriasis in France (2016-2027)
  • Table 23: Severity Specific Diagnosed Prevalence of Psoriasis in the France (2016-2027)
  • Table 24: Treatable Population of Psoriasis by Therapies in the France (2016-2027)
  • Table 25: Treatable Population of Psoriasis by Phototherapies type in France (2016-2027)
  • Table 26: Total Prevalent Population of Psoriasis in Italy (2016-2027)
  • Table 27: Total Diagnosed Prevalent Population of Psoriasis in Italy (2016-2027)
  • Table 28: Severity Specific Diagnosed Prevalence of Psoriasis in the Italy (2016-2027)
  • Table 29: Treatable Population of Psoriasis by Therapies in the Italy (2016-2027)
  • Table 30: Treatable Population of Psoriasis by Phototherapies type in Italy (2016-2027)
  • Table 31: Total Prevalent Population of Psoriasis in Spain (2016-2027)
  • Table 32: Total Diagnosed Prevalent Population of Psoriasis in Spain (2016-2027)
  • Table 33: Severity Specific Diagnosed Prevalence of Psoriasis in the Spain (2016-2027)
  • Table 34: Treatable Population of Psoriasis by Therapies in the Spain (2016-2027)
  • Table 35: Treatable Population of Psoriasis by Phototherapies type in Spain (2016-2027)
  • Table 36: Total Prevalent Population of Psoriasis in the United Kingdom (2016-2027)
  • Table 37: Total Diagnosed Prevalent Population of Psoriasis in the UK (2016-2027)
  • Table 38: Severity Specific Diagnosed Prevalence of Psoriasis in the UK (2016-2027)
  • Table 39: Treatable Population of Psoriasis by Therapies in the United Kingdom (2016-2027)
  • Table 40: Treatable Population of Psoriasis by Phototherapies type in the United Kingdom (2016-2027)
  • Table 41: Treatment of Psoriasis in Problem Areas
  • Table 42: Corticosteroids Classifications
  • Table 43: Therapy for Generalized Psoriasis
  • Table 44: Recommendations for Alefacept
  • Table 45: Recommendations for Efalizumab
  • Table 46: Recommendations for Adalimumab
  • Table 47: Recommendations for Etanercept
  • Table 48: Recommendations for Infliximab
  • Table 49: Recommendations for Topical Corticosteroids
  • Table 50: Recommendations for Vitamin D analogues
  • Table 51: Recommendations for Topical Tazarotene
  • Table 52: Recommendations for Topical Tacrolimus and Pimecrolimus
  • Table 53: Recommendations for Emollients
  • Table 54: Recommendations for Salicylic acid
  • Table 55: Recommendations for Anthralin
  • Table 56: Recommendations for Coal tar
  • Table 57: Recommendations for Methotrexate
  • Table 58: Recommendations for Cyclosporine
  • Table 59: Recommendations for Azathioprine
  • Table 60: Recommendations for Fumaric acid esters
  • Table 61: Recommendations for Hydroxyurea
  • Table 62: Recommendations for Leflunomide
  • Table 63: Recommendations for Mycophenolate mofetil
  • Table 64: Recommendations for Sulfasalazine
  • Table 65: Recommendations for Tacrolimus
  • Table 66: Recommendations for 6-thioguanine
  • Table 67: Recommendations for Ultraviolet B (Broadband and Narrowband)
  • Table 68: Recommendations for use of topical targeted phototherapy
  • Table 69: Recommendations for use of systemic psoralen plus ultraviolet A
  • Table 70: Recommendations for use of topical psoralen plus ultraviolet A
  • Table 71: Phototherapeutics for Psoriasis
  • Table 72: Total Market Size of Phototherapy for Psoriasis in the US, EU5 & RoW, in USD Million (2016-2027)
  • Table 73: Market Size of Phototherapy for Psoriasis in the United States, USD Millions (2016-2027)
  • Table 74: Market size by Phototherapy type in the US, in USD Million (2016-2027)
  • Table 75: Market size of Phototherapy for Psoriasis by End Users in the US, in USD Million (2016-2027)
  • Table 76: Market Size of Phototherapy for Psoriasis in Germany, USD Millions (2016-2027)
  • Table 77: Market size by Phototherapy type in Germany, in USD Million (2016-2027)
  • Table 78: Market size of Phototherapy for Psoriasis by End Users in Germany, in USD Million (2016-2027)
  • Table 79: Market Size of Phototherapy for Psoriasis in France, USD Millions (2016-2027)
  • Table 80: Market size by Phototherapy type in France, in USD Million (2016-2027)
  • Table 81: Market size of Phototherapy for Psoriasis by End Users in France, in USD Million (2016-2027)
  • Table 82: Market Size of Phototherapy for Psoriasis in France, USD Millions (2016-2027)
  • Table 83: Market size by Phototherapy type in Italy, in USD Million (2016-2027)
  • Table 84: Market size of Phototherapy for Psoriasis by End Users in Italy, in USD Million (2016-2027)
  • Table 85: Market Size of Phototherapy for Psoriasis in Spain, USD Millions (2016-2027)
  • Table 86: Market size by Phototherapy type in Spain, in USD Million (2016-2027)
  • Table 87: Market size of Phototherapy for Psoriasis by End Users in Spain, in USD Million (2016-2027)
  • Table 88: Market Size of Phototherapy for Psoriasis in UK, USD Millions (2016-2027)
  • Table 89: Market size by Phototherapy type in UK, in USD Million (2016-2027)
  • Table 90: Market size of Phototherapy for Psoriasis by End Users in UK, in USD Million (2016-2027)
  • Table 91:Market Size of Phototherapy for Psoriasis in RoW, USD Millions (2016-2027)

List of Figures

  • Figure 1: Total Prevalent Patient Population of Psoriasis in United States and EU5 (2016-2027)
  • Figure 2: Total Treatable Patient Population of Psoriasis by Phototherapies in United States and EU5 (2016-2027)
  • Figure 3: Total Prevalent Population of Psoriasis in the United States (2016-2027)
  • Figure 4: Diagnosed Prevalence of Psoriasis in the United States (2016-2027)
  • Figure 5: Severity Specific Diagnosed Prevalence of Psoriasis in the United States (2016-2027)
  • Figure 6: Treatable Population of Psoriasis by Therapies in the United States (2016-2027)
  • Figure 7: Treatable Population of Psoriasis by Phototherapies type in the United States (2016-2027)
  • Figure 8: Total Prevalent Population of Psoriasis in Germany (2016-2027)
  • Figure 9: Total Diagnosed Prevalent Population of Psoriasis in Germany (2016-2027)
  • Figure 10: Type Specific Diagnosed Prevalence of Psoriasis in Germany (2016-2027)
  • Figure 11: Treatable Population of Psoriasis by Therapies in Germany (2016-2027)
  • Figure 12: Treatable Population of Psoriasis by Phototherapies type in Germany (2016-2027)
  • Figure 13: Total Prevalent Population of Psoriasis in France (2016-2027)
  • Figure 14: Total Diagnosed Prevalent Population of Psoriasis in France (2016-2027)
  • Figure 15: Severity Specific Diagnosed Prevalence of Psoriasis in France (2016-2027)
  • Figure 16: Treatable Population of Psoriasis by Therapies in France (2016-2027)
  • Figure 17: Treatable Population of Psoriasis by Phototherapies type in France (2016-2027)
  • Figure 18: Total Prevalent Population of Psoriasis in Italy (2016-2027)
  • Figure 19: Total Diagnosed Prevalent Population of Psoriasis in Italy (2016-2027)
  • Figure 20: Severity Specific Diagnosed Prevalence of Psoriasis in Italy (2016-2027)
  • Figure 21: Treatable Population of Psoriasis by Therapies in Italy (2016-2027)
  • Figure 22: Treatable Population of Psoriasis by Phototherapies type in Italy (2016-2027)
  • Figure 23: Total Prevalent Population of Psoriasis in Spain (2016-2027)
  • Figure 24: Total Diagnosed Prevalent Population of Psoriasis in Spain (2016-2027)
  • Figure 25: Severity Specific Diagnosed Prevalence of Psoriasis in Spain (2016-2027)
  • Figure 26: Treatable Population of Psoriasis by Therapies in Spain (2016-2027)
  • Figure 27: Treatable Population of Psoriasis by Phototherapies type in Spain (2016-2027)
  • Figure 28: Total Prevalent Population of Psoriasis in the United Kingdom (2016-2027)
  • Figure 29: Total Diagnosed Prevalent Population of Psoriasis in the UK (2016-2027)
  • Figure 30: Severity Specific Diagnosed Prevalence of Psoriasis in the UK (2016-2027)
  • Figure 31: Treatable Population of Psoriasis by Therapies in the United Kingdom (2016-2027)
  • Figure 32: Treatable Population of Psoriasis by Phototherapies type in the United Kingdom (2016-2027)
  • Figure 33: Unmet Needs of Phototherapy for psoriasis
  • Figure 34: Total Market Size of Phototherapy for Psoriasis in the US, EU5 & RoW, in USD Million (2016-2027)
  • Figure 35: Market Size of Phototherapy for Psoriasis in the United States, USD Millions (2016-2027)
  • Figure 36: Market size by Phototherapy type in the US, in USD Million (2016-2027)
  • Figure 37: Market size of Phototherapy for Psoriasis by End Users in the US, in USD Million (2016-2027)
  • Figure 38: Market Size of Phototherapy for Psoriasis in Germany, USD Millions (2016-2027)
  • Figure 39: Market size by Phototherapy type in Germany, in USD Million (2016-2027)
  • Figure 40: Market size of Phototherapy for Psoriasis by End Users in Germany, in USD Million (2016-2027)
  • Figure 41: Market Size of Phototherapy for Psoriasis in France, USD Millions (2016-2027)
  • Figure 42: Market size by Phototherapy type in France, in USD Million (2016-2027)
  • Figure 43: Market size of Phototherapy for Psoriasis by End Users in France, in USD Million (2016-2027)
  • Figure 44: Market Size of Phototherapy for Psoriasis in Italy, USD Millions (2016-2027)
  • Figure 45: Market size by Phototherapy type in Italy, in USD Million (2016-2027)
  • Figure 46: Market size of Phototherapy for Psoriasis by End Users in Italy, in USD Million (2016-2027)
  • Figure 47: Market Size of Phototherapy for Psoriasis in Spain, USD Millions (2016-2027)
  • Figure 48: Market size by Phototherapy type in Spain, in USD Million (2016-2027)
  • Figure 49: Market size of Phototherapy for Psoriasis by End Users in Spain, in USD Million (2016-2027)
  • Figure 50: Market Size of Phototherapy for Psoriasis in UK, USD Millions (2016-2027)
  • Figure 51: Market size by Phototherapy type in UK, in USD Million (2016-2027)
  • Figure 52: Market size of Phototherapy for Psoriasis by End Users in UK, in USD Million (2016-2027)
  • Figure 53: Market Size of Phototherapy for Psoriasis in RoW, USD Millions (2016-2027)
  • Figure 54: Market Driver
  • Figure 55:Market Barriers
Back to Top